CA2545802A1 - Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients - Google Patents

Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients Download PDF

Info

Publication number
CA2545802A1
CA2545802A1 CA002545802A CA2545802A CA2545802A1 CA 2545802 A1 CA2545802 A1 CA 2545802A1 CA 002545802 A CA002545802 A CA 002545802A CA 2545802 A CA2545802 A CA 2545802A CA 2545802 A1 CA2545802 A1 CA 2545802A1
Authority
CA
Canada
Prior art keywords
disorder
disease
physiologically acceptable
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002545802A
Other languages
English (en)
French (fr)
Inventor
Dirk Thormaehlen
Berthold Hocher
Harald Waldeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2545802A1 publication Critical patent/CA2545802A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002545802A 2003-11-18 2004-11-15 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients Abandoned CA2545802A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104264.1 2003-11-18
EP03104264 2003-11-18
PCT/EP2004/052963 WO2005049035A1 (en) 2003-11-18 2004-11-15 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients

Publications (1)

Publication Number Publication Date
CA2545802A1 true CA2545802A1 (en) 2005-06-02

Family

ID=34610099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002545802A Abandoned CA2545802A1 (en) 2003-11-18 2004-11-15 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients

Country Status (15)

Country Link
US (1) US7273860B2 (https=)
EP (1) EP1687006B1 (https=)
JP (1) JP4824573B2 (https=)
CN (1) CN100566719C (https=)
AR (1) AR046454A1 (https=)
AT (1) ATE378053T1 (https=)
AU (1) AU2004290925B2 (https=)
BR (1) BRPI0416706A (https=)
CA (1) CA2545802A1 (https=)
DE (1) DE602004010172T2 (https=)
ES (1) ES2297536T3 (https=)
MX (1) MXPA06005547A (https=)
PL (1) PL1687006T3 (https=)
TW (1) TWI344366B (https=)
WO (1) WO2005049035A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60040089D1 (de) * 1999-11-19 2008-10-09 Solvay Pharm Bv Menschliches homolog aus der familie der metalloproteasen
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
TWI741240B (zh) * 2017-12-11 2021-10-01 日商埃塔斯製藥股份有限公司 含有1,4-苯并硫氮呯-1-氧化物衍生物之光學異構物之腎功能障礙的改善藥
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
CN112292125B (zh) * 2018-06-22 2023-10-31 西奈克制药有限公司 蛋白尿的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
RU2303041C2 (ru) * 2002-01-16 2007-07-20 Солвей Фармасьютикалс Б.В. Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos

Also Published As

Publication number Publication date
JP2007511582A (ja) 2007-05-10
AR046454A1 (es) 2005-12-07
DE602004010172D1 (de) 2007-12-27
PL1687006T3 (pl) 2008-01-31
HK1097762A1 (zh) 2007-07-06
ATE378053T1 (de) 2007-11-15
TW200526228A (en) 2005-08-16
JP4824573B2 (ja) 2011-11-30
AU2004290925A1 (en) 2005-06-02
AU2004290925B2 (en) 2010-07-01
CN100566719C (zh) 2009-12-09
CN1878557A (zh) 2006-12-13
US20050137183A1 (en) 2005-06-23
US7273860B2 (en) 2007-09-25
DE602004010172T2 (de) 2008-09-11
EP1687006B1 (en) 2007-11-14
MXPA06005547A (es) 2006-08-17
TWI344366B (en) 2011-07-01
BRPI0416706A (pt) 2007-01-16
EP1687006A1 (en) 2006-08-09
WO2005049035A1 (en) 2005-06-02
ES2297536T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
AU686706B2 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
CN102834099B (zh) Dgat1抑制剂的用途
JP2002533415A (ja) 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ
SK10822001A3 (sk) Liek na liečenie vysokého krvného tlaku
EP1687006B1 (en) Pharmaceutical compositions for the treatment of renal dysfunction
CA2516730A1 (en) Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
KR101577554B1 (ko) Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
CA2513281A1 (en) Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
CA2036774A1 (en) Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor and/or thromboxane receptorantagonist or a
RU2423692C2 (ru) Вещества для профилактики и лечения панкреатита
EP4706758A2 (en) Methods for inhibiting phosphate transport
JP2002220345A (ja) 脂肪肝改善剤
US20080242684A1 (en) Methods of administration of adenosine a1 receptor antagonists
EA018442B1 (ru) Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
HK1097762B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
JP5559696B2 (ja) 糖尿病性腎症の治療剤
MX2013013124A (es) Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
JPH06211657A (ja) 尿酸排泄剤
MA Al-Hayali et al. Effect of amlodipine on serum lipid profilein hypertensive patients
JP2002535369A (ja) 糖尿病を治療するための組成物及び方法
JPH1081632A (ja) 医 薬
JP2000297038A (ja) 医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20121115